Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Diabetes is a chronic disease that occurs when impaired pancreases cannot synthesize insulin in body or when the body cannot uptake insulin for glucose utilization. Diabetes naturally increase the risk of other diseases with it such as cardiovascular disorders, neuropathy, kidney damage, eye complications etc.
According to World Health Organisation (WHO), worldwide prevalence of diabetes among adults has risen from 4.7% to 8.5% from 2014 to 2019 and is growing quickly in middle and low-income countries. Furthermore, the Centers for Disease Control and Prevention stated that diabetes is the seventh foremost cause of mortality in the U.S. and is the number one cause of adult blindness and kidney failure. As there is no treatment available to cure diabetes completely and rapidly rising diabetic population demands to build the awareness among the people about standard treatments for diabetic diagnosis and care.
Unhealthy lifestyles & urbanization, rising number of cases of diabetes of both type 1 and type 2 and new technological innovations are the driving factors affecting the diabetes drug market. However, stringent regulatory guidelines and time consuming approval process by regulatory bodies are hampering the market growth.
The diabetes drug market is segmented by drug type, application and geography.
The diabetes drugs are classified as oral anti-diabetic drugs, insulin, non-insulin injectable drugs and combination drugs. Oral anti-diabetic drugs are further segmented as biguanides (metformin), alpha-glucosidase inhibitors (voglibose, milglotol etc.), dopamine -d2 receptor agonist (bromocriptin), sodium-glucose cotransport -2 (SGLT-2) inhibitors (canagliflozin, empagliflozin, dapagliflozin,ipragliflozin etc.), dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin etc.) sulfonylureas (glipizide, glimepiride etc.) and meglitinides (repaglinide,nateglinide etc.) insulin, depending upon its duration of action is categorised as basal or long-acting insulin (insulin detemir, insulin glargine and insulin degludec), bolus or fast-acting insulin (insulin aspart, insulin lispro and insulin glulisine), and traditional human insulin (NPH insulin and regular insulin). Non-insulin injectable drugs are divided into two parts, 1 GLP-1 receptor agonists (liraglutid, exenatide, dulaglutide, lixisenatide etc.) and amylin analogue (pramlintide). Combination drugs are categorised as a combination of insulin (biphasic insulin aspart, insulin degludec & aspart and insulin degludec & liraglutide) and oral drugs combinations (sitagliptin and metformin HCL).
The diabetes drugs are used in treating type 1 diabetes and type 2 diabetes. Type 1 diabetic patients are treated with insulin as the patient’s body cannot synthesize insulin itself. In type 2 diabetes the body become resistant to insulin or very low amount of insulin is produced which is treated with drugs therapy including use of oral anti-diabetic agents such as sulfonylureas, biguanides etc.
The diabetes drugs report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. North America dominated the market for diabetes drugs in 2018, owing to the rising aged population, high prevalence of diabetes and high healthcare expenditure. Whereas, Asia Pacific is expected to witness the fastest growth rate during the forecast period 2019 to 2025 owing to increasing investment by the government to improve medical and healthcare scenarios in the regions.
Some leading players operating in this market includes Astellas Pharma Inc., AstraZeneca plc, Boehringer Ingelheim Limited, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceuticals, Inc. , Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd, Abbott laboratories, Bayer AG, Biocon ltd., Dr. Reddy's laboratories ltd, Ranbaxy laboratories ltd, Lupin Pharmaceuticals, Inc., GlaxoSmithKline plc., Piramal healthcare ltd, Gan & Lee Pharmaceuticals. and Wanbang Biopharmaceuticals Co., Ltd.. Key strategies implemented by the diabetes drugs industries to improve the revenue are new product launch, collaboration and acquisitions with other organizations. For example, in April 2019: Novo Nordisk launched Victoza (Liraglutide), potential new treatment for children and adolescent type 2 diabetes. Liraglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
The diabetes drugs market is segmented by drug type, application and geography. The diabetes drug market by drug type is classified as oral anti-diabetic drugs, insulin, non-insulin injectable drugs and combination drugs. The diabetes drugs are used in treat type 1 diabetes and type 2 diabetes. Unhealthy lifestyles & urbanization is one of the major cause of diabetes.
The diabetes drugs report is examined across the key countries of North America, Europe, Asia Pacific and Rest of the World. North America dominated the market for diabetes drugs followed by for the highest market value in 2018, owing to the growing aged population, high occurrence of diabetic patients and high healthcare expenditure.
New product launch, collaboration and acquisitions with other organizations are the key strategies implemented by the diabetes drugs industries to improve the market development.
Why to buy this report:
